As a research service provider, Illarion supports biotech and pharmaceutical companies in making challenging targets such as transcription factors and membrane proteins accessible for drug development. Through highly efficient biophysical assays, the company helps partners overcome critical hurdles in early-stage drug discovery faster and with greater precision.

“Our goal is to significantly accelerate our customers' journey toward clinical trials through innovative biophysical technologies,” says Dr. Reto Walser, founder of Illarion AG. “The decision to join Park Innovaare was strategically essential for us. The proximity to the unique environment of one of the world’s leading large-scale research facilities at the Paul Scherrer Institut, combined with the concentrated expertise in structural biology, perfectly complements our know-how.”

With Illarion, Park Innovaare further strengthens its competencies in structural biology, drug discovery, and applied biophysics. The close proximity to PSI’s research infrastructure, together with a strong network of deep-tech and life sciences companies, creates ideal conditions for scientific exchange and industrial collaboration.

We warmly welcome Dr. Reto Walser and his team and look forward to supporting their continued growth within our innovation ecosystem.

Visit Illarion AG:
www.illarion.com